Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on November 15, 2025 to three new non-executive employees under its 2025 Inducement Plan. The independent Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants total 2,125 time-based restricted stock units (RSUs), vesting in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.
Madrigal Pharmaceuticals (NASDAQ:MDGL) ha concesso premi di induzione azionaria il 15 novembre 2025 a tre nuovi dipendenti non executive, ai sensi del Piano di Induzione 2025. Il Comitato indipendente per la retribuzione ha approvato i premi in conformità al Nasdaq Listing Rule 5635(c)(4).
Le assegnazioni ammontano a 2.125 restricted stock unit (RSU) a tempo, che maturano in quattro rate annuali uguali, alla prima, seconda, terza e quarta anniversario della data di concessione, soggette all'occupazione continuata.
Madrigal Pharmaceuticals (NASDAQ:MDGL) concedió premios de inducción de acciones el 15 de noviembre de 2025 a tres nuevos empleados no ejecutivos bajo su Plan de Inducción 2025. El Comité Independiente de Compensación aprobó los premios de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4).
Las concesiones totalizan 2.125 unidades de acciones restringidas (RSU) a tiempo, que se adquieren en cuatro anualidades iguales en cada uno de los primeros cuatro aniversarios de la fecha de concesión, sujeto a la continuidad del empleo.
마드리갈 파마슈티컬스(NASDAQ:MDGL)은 2025년 11월 15일에 2025 Inducement Plan에 따라 세 명의 신규 비임원 직원에게 지분 인센티브 보상을 부여했습니다. 독립 보상 위원회가 Nasdaq Listing Rule 5635(c)(4)에 따라 보상을 승인했습니다.
총 보상은 2,125시간 기반의 제한 주식 단위(RSU)로, 부여일로부터 첫 해부터 네 번째 해의 각 기념일에 대해 동등한 네 번의 연간 분할로 취득되며, 지속 근무 조건에 따라 다릅니다.
Madrigal Pharmaceuticals (NASDAQ:MDGL) a accordé des attributions d'incitation en actions le 15 novembre 2025 à trois nouveaux employés non cadres dans le cadre de son Plan d'induction 2025. Le Comité indépendant de rémunération a approuvé les attributions conformément à la Règle 5635(c)(4) de Nasdaq Listing.
Les attributions totalisent 2 125 unités d'actions restreintes à temps (RSU), qui s'acquièrent par paliers annuels égaux à chacune des quatre premières annuités à la date d'octroi, sous réserve du maintien en emploi.
Madrigal Pharmaceuticals (NASDAQ:MDGL) gewährt Aktien-Bonus-Awards am 15. November 2025 an drei neue nicht leitende Mitarbeitende im Rahmen ihres 2025 Inducement Plans. Der unabhängige Vergütungsausschuss hat die Zuwendungen gemäß der Nasdaq Listing Rule 5635(c)(4) genehmigt.
Die Zuwendungen belaufen sich auf 2.125 zeitbasierte Restricted Stock Units (RSUs), die in vier gleichen jährlichen Raten an den ersten bis vierten Jahrestag des Gewährungsdatums vesten, vorbehaltlich der fortgesetzten Beschäftigung.
شركة مادرغيل للأدوية (ناسداك: MDGL) منحت جوائز حافز أسهم في 15 نوفمبر 2025 لثلاثة موظفين جدد غير تنفيذيين بموجب خطة الحافز لعام 2025. قسم التعويض المستقل وافق على الجوائز وفقاً لـ قاعدة إدراج ناسداك 5635(c)(4).
إجمالي المنح 2,125 وحدة أسهم مقيدة زمنياً (RSUs)، تتقادم في أربع دفعات سنوية متساوية في كل من الذكرى الأولى حتى الرابعة لتاريخ المنح، رهناً باستمرار التوظيف.
- None.
- None.
CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 15, 2025 to three new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 2,125 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
What did Madrigal (MDGL) announce on November 20, 2025 about employee equity awards?
How do the Madrigal (MDGL) RSUs vest and what are the conditions?
Under which plan and Nasdaq rule were the Madrigal (MDGL) inducement awards approved?
How many employees received inducement awards from Madrigal (MDGL) and when were they granted?
Will Madrigal (MDGL) RSU vesting occur if an employee leaves before a vesting date?
